GL
RPRX icon

Graypoint LLC’s Royalty Pharma RPRX Stock Holding History

Graypoint LLC’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$1.27M Buy
35,192
+8
+0% +$265 0.07% 181
2025
Q1 		$1.1M Hold
35,184
– – 0.07% 187
2024
Q4 		$898K Sell
35,184
-13
-0% -$345 0.05% 209
2024
Q3 		$996K Buy
35,197
+2
+0% +$55 0.06% 191
2024
Q2 		$928K Sell
35,195
-8,826
-20% -$245K 0.06% 188
2024
Q1 		$1.34M Sell
44,021
-6
-0% -$177 0.1% 149
2023
Q4 		$1.24M Buy
44,027
+32
+0.1% +$879 0.1% 145
2023
Q3 		$1.19M Buy
43,995
+46
+0.1% +$1.37K 0.11% 134
2023
Q2 		$1.35M Hold
43,949
– – 0.13% 114
2023
Q1 		$1.58M Sell
43,949
-26
-0.1% -$964 0.17% 97
2022
Q4 		$1.74M Sell
43,975
-40,026
-48% -$1.67M 0.21% 90
2022
Q3 		$3.38M Hold
84,001
– – 0.43% 57
2022
Q2 		$3.53M Sell
84,001
-481,673
-85% -$19.7M 0.45% 56
2022
Q1 		$22M Buy
565,674
+90
+0% +$3.53K 2.18% 10
2021
Q4 		$22.5M Sell
565,584
-45,000
-7% -$1.75M 2.36% 9
2021
Q3 		$22.1M Buy
610,584
+430,668
+239% +$16.7M 2.71% 7
2021
Q2 		$7.38M Buy
+179,916
New +$7.65M 0.98% 30

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CIA
Caledonia Investments (Australia) Sydney NSW, Australia $3.44B AUM 20.03% 1-Year Est. Return

Graypoint LLC's RPRX Position: Q2 2025 in Review

Graypoint LLC increased its Royalty Pharma (RPRX) stake by 0.02% in Q2 2025, buying an estimated $265 and bringing the position to 35,192 shares worth $1.27M. The position accounts for 0.07% of the portfolio, ranked #181.

Graypoint LLC first reported a position in RPRX in Q2 2021 and has held it in 17 quarters since. The position peaked at $22.5M in Q4 2021. 455 funds tracked by Wall St. Rank hold RPRX as of Q2 2025.

  • Graypoint LLC held 35,192 shares of Royalty Pharma worth $1.27M as of Q2 2025.
  • Graypoint LLC bought 8 Royalty Pharma shares in Q2 2025, an estimated $265.
  • Royalty Pharma made up 0.07% of Graypoint LLC's portfolio in Q2 2025, its #181 holding.
  • Graypoint LLC first reported a position in Royalty Pharma in Q2 2021 and has held it in 17 quarters since.
  • Graypoint LLC's Royalty Pharma position peaked at $22.5M in Q4 2021.
  • 455 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2025.

Based on Graypoint LLC's 13F filing for Q2 2025, filed 15 Jul 2025.